Studying a catalyst for blood cancers

April 25, 2017, University of Miami Leonard M. Miller School of Medicine
A tumor-cell infiltration into the liver of a Tet2-ko mouse. Credit: Sylvester Comprehensive Cancer Center

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the original motorist - the one who caused the problem - drives on.

This is similar to what happens with the protein TET2 and a variety of blood cancers. TET2 is a tumor suppressor, preventing hematopoietic (blood) stem cells from overgrowing. However, if TET2 becomes mutated, which happens more frequently than we like, it allows other genes to mutate. TET2 loss does not actually create a cancerous state, but it helps create the conditions for cancer to thrive.

"If you lose TET2, it's not a malignant state, per se," said Mingjiang Xu, M.D., Ph.D., cancer researcher at Sylvester Comprehensive Cancer Center and associate professor of biochemistry and molecular biology at the University of Miami Miller School of Medicine. "But it's creating a situation for other mutations to happen, leading to all types of blood cancer."

Xu and colleagues have been studying Tet2 for several years, and are starting to get a handle on how it operates. They published a paper today in the prestigious journal Nature Communications, which describes how TET2 loss can open the door for mutations that drive myeloid, lymphoid, and other cancers.

A different kind of mutation

That TET2 has a hand in several blood cancers makes it unique. Many mutated genes generate a specific type of cancer, depending on where they originate.

"If you lose TET2, it leads to blood cancers and it could be any type," said Xu. "Usually if you lose one gene, it leads to one specific cancer."

TET2 is an enzyme that demethylates DNA. Methylation turns down genes, keeping them from coding for specific proteins. In other words, TET2 may operate as a master switch, controlling whether certain are turned on or off.

TET2 mutations are found in 30 percent of myelodysplastic syndrome (MDS); 30 percent of secondary acute myeloid leukemias; and more than 50 percent of chronic myelomonocytic leukemias.

In the Nature Communications paper, Xu's team showed that mice without the Tet2 gene are more prone to . In fact, removing Tet2 turns blood stem cells into mutation machines, and some of those malfunctions generate cancer.

Targeting Tet2

From a clinical standpoint, TET2 is a little tricky. First, it is easier to turn a protein off than turn it on. In addition, TET2 does not actually drive the cancer alone - it's the mutations acquired cooperate with the TET2 loss doing that nasty work. Turning up Tet2 could be helpful, but it has to happen early. Once the mutations are generated, targeting Tet2 would have little effect.

Still, Xu believes TET2 therapeutics could have a place in treatment. He notes that around 5 percent of people over the age of 70 have TET2 mutations, which would make them ideal candidates for a preventive therapy.

"We are developing a method to target TET2," said Xu. "If we target that population for early therapy, we could potentially prevent those downstream from happening."

Explore further: Gene mutation contributes to leukemia by enhancing function of blood stem cells

Related Stories

Gene mutation contributes to leukemia by enhancing function of blood stem cells

July 1, 2011
Researchers at Memorial Sloan-Kettering Cancer Center and New York University have discovered how a mutation in the gene known as TET2 contributes to the development of some leukemias. When a mutation in TET2 occurs, it enhances ...

New study changes view about the genetics of leukemia risk

October 11, 2013
(Medical Xpress)—A gene that helps keep blood free of cancer is controlled by tiny pieces of RNA, a finding that may lead to better ways to diagnose blood cancers and even lead to new forms of treatment, Yale School of ...

TET proteins help maintain genome integrity

December 9, 2015
Members of the TET (short for ten-eleven translocation) family have been known to function as tumor suppressors for many years, but how they keep a lid on the uncontrolled cell proliferation of cancer cells had remained uncertain. ...

Dual loss of TET proteins prompts lethal upsurge in inflammatory T cells in a mouse model

December 12, 2016
Members of the TET family of proteins help protect against cancer by regulating the chemical state of DNA —and thus turning growth-promoting genes on or off. The latest findings reported by researchers at La Jolla Institute ...

A role for mutated blood cells in heart disease?

January 19, 2017
A new study provides some of the first links between relatively common mutations in the blood cells of elderly humans and atherosclerosis.

The TET1 enzyme steers us through fetal development and fights cancer

April 13, 2011
To ensure normal fetal development and prevent disease, it is crucial that certain genes are on or off in the right time intervals. Researchers in Professor Kristian Helin's group at BRIC, University of Copenhagen, have now ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.